Intestinal Disease Clinical Trial
Official title:
Enteral Administration of Lactated Ringer's Solution in Neonates With Feeding Intolerance, a Randomized Controlled Trial
The objective of this study is determining if enteral administration of Lactated Ringer's solution (LR) in preterm infants with feeding intolerance enables for faster advancement of milk feeding than fasting.
Feeding intolerance is a common problem in premature infants in the Neonatal Intensive Care
Unit. Definition is clinical and based on abdominal distension, abdominal tenderness,
emesis, change in gastric residuals, presence of blood in stool, and apnea with bradycardia.
Feeding intolerance is associated with serious complications: necrotizing enterocolitis,
longer hospitalization and prolonged intravenous nutrition complications (e.g. sepsis, liver
damage). Therefore, the investigators aim to achieve adequate enteral nutrition as soon as
possible.
Because LR is a an amniotic fluid-like solution, it may improve gastro-intestinal function
and avoid fasting, as well as its multiple problems (e.g. intestinal atrophy and decreased
intestinal motility). LR was chosen as the test solution because of experience documenting
its safe use in comparable groups: in newborn resuscitation parenterally, in amnioinfusion,
and in bowel irrigation. Moreover, LR is similar in electrolytes composition to the
experimental solution used in previous studies by Barney et al in neonates.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Recruiting |
NCT05194527 -
The Detrimental Course of Acute Intestinal Ischemia
|
||
| Recruiting |
NCT04605627 -
The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease.
|
||
| Enrolling by invitation |
NCT04502784 -
Investigation of Hypophosphataemia Following Intravenous Iron
|
||
| Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03723447 -
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
|
Phase 4 | |
| Completed |
NCT04573959 -
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
|
N/A | |
| Not yet recruiting |
NCT04123990 -
Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease
|
N/A | |
| Not yet recruiting |
NCT06271538 -
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
|
Phase 4 | |
| Completed |
NCT02785783 -
Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
|
N/A | |
| Completed |
NCT03012594 -
Lanreotide in the Treatment of Small Bowel Motility Disorders
|
Phase 2 | |
| Recruiting |
NCT06007313 -
Mental Stress and Bowel Preparation Quality
|
||
| Completed |
NCT04982302 -
Gut Microbial Changes After Periodontal Treatment
|
||
| Completed |
NCT03543540 -
Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease
|
Phase 1 | |
| Completed |
NCT03817645 -
Panaceo "MED" for IBS (Irritable Bowel Syndrome)
|
N/A | |
| Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03280407 -
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Completed |
NCT04263818 -
Endoscopist and Endoscope Motions During Colonoscopy
|
N/A | |
| Recruiting |
NCT05923918 -
A Study to Evaluate Safety and Efficacy of PBK_M2101
|
Phase 3 |